Partial Overview of 2024 Annual Reports of Chinese IVD Companies

Sinocare

On April 20, 2024, Sinocare Inc. released its 2024 annual report. The company achieved an operating revenue of RMB 4.443 billion, a year-on-year increase of 9.47%. Net profit attributable to the parent company was RMB 326 million, a year-on-year increase of 14.73%. Net cash flow from operating activities was RMB 631 million, a year-on-year decrease of 14.13%.

Gongdong Medical
On April 21, 2024, Zhejiang Gongdong Medical Technology Co., Ltd. released its 2024 annual report. The company achieved an operating revenue of RMB 1.115 billion, a year-on-year increase of 14.37%. Net profit attributable to the parent company was RMB 172 million, a year-on-year increase of 57.28%. Net cash flow from operating activities was RMB 210 million, a year-on-year increase of 13.48%.

AmoyDx

On April 21, 2024, Xiamen AmoyDx Biotechnology Co., Ltd. released its 2024 annual report. The company achieved an operating revenue of RMB 1.109 billion, a year-on-year increase of 6.27%. Net profit attributable to the parent company was RMB 255 million, a year-on-year decrease of 2.53%. Net cash flow from operating activities was RMB 342 million, a year-on-year increase of 14.44%.

Dian Diagnostics

On April 22, 2024, Dian Diagnostics Group Co., Ltd. released its 2024 annual report. The company achieved an operating revenue of RMB 12.196 billion, a year-on-year decrease of 9.04%. Net profit attributable to the parent company was RMB -357 million, a year-on-year decrease of 216.20%. Net cash flow from operating activities was RMB 1.207 billion, a year-on-year decrease of 37.16%.

YHLO

On April 24, 2024, Shenzhen YHLO Biotech Co., Ltd. released its 2024 annual report. The company achieved an operating revenue of RMB 2.011 billion, a year-on-year decrease of 2.02%. Net profit attributable to the parent company was RMB 302 million, a year-on-year decrease of 15.06%. Net cash flow from operating activities was RMB 530 million.

Easy Diagnosis

On April 24, 2024, Wuhan Easy Diagnosis Biotechnology Co., Ltd. released its 2024 annual report. The company achieved an operating revenue of RMB 350 million, a year-on-year decrease of 53.30%. Net profit attributable to the parent company was RMB 75 million, a year-on-year decrease of 0.54%. Net cash flow from operating activities was RMB -85 million, a year-on-year decrease of 121.67%.

Snibe Diagnostic

On April 25, 2024, Shenzhen New Industry Biomedical Engineering Co., Ltd. released its 2024 annual report. The company achieved an operating revenue of RMB 4.535 billion, a year-on-year increase of 15.41%. Net profit attributable to the parent company was RMB 1.828 billion, a year-on-year increase of 10.57%. Net cash flow from operating activities was RMB 1.356 billion, a year-on-year decrease of 4.36%.

Kehua Bio-Engineering

On April 27, 2024, Shanghai Kehua Bio-Engineering Co., Ltd. released its 2024 annual report. The company achieved an operating revenue of RMB 1.759 billion, a year-on-year decrease of 27.55%. Net profit attributable to the parent company was RMB -641 million, a year-on-year decrease of 173.74%. Net cash flow from operating activities was RMB -50 million, a year-on-year increase of 89.45%.

Labway Clinical

On April 27, 2024, Shanghai Labway Clinical Laboratory Co., Ltd. released its 2024 annual report. The company achieved an operating revenue of RMB 1.742 billion, a year-on-year increase of 4.05%. Net profit attributable to the parent company was RMB -109 million, a year-on-year increase of 22.71%. Net cash flow from operating activities was RMB 216 million, a year-on-year decrease of 60.45%.